Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies
Conditions
Interventions
LP352
Placebo
Locations
34
United States
University of Arizona - Health Sciences Center
Tucson, Arizona, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Rancho Los Amigos National Rehabilitation Center (RLANRC)
Downey, California, United States
Children's Hospital of Orange County
Orange, California, United States
University of California San Francisco
San Francisco, California, United States
Northwest Florida Clinical Research Group
Gulf Breeze, Florida, United States
Start Date
March 3, 2022
Primary Completion Date
November 16, 2023
Completion Date
November 20, 2023
Last Updated
November 8, 2024
NCT06872125
NCT05419492
NCT07010471
NCT05066217
NCT04462770
NCT06401538
Lead Sponsor
Longboard Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions